Evidence map›Paper›PMID 42041311›Full record

ArticleAntibiotics (Basel, Switzerland)2026

Cefiderocol Is Effective In Vitro Against Numerous Gram-Negative Species Isolated from Keratitis Patients.

Jonathan B Mandell, Robert M Q Shanks, Eric G Romanowski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathan B MandellThe Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
Robert M Q ShanksThe Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
Eric G RomanowskiThe Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.ORCID 0000-0003-4246-3276

Funding

Virus Production and Manipulation of Protein/Gene Expression ModuleP30EY008098 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Yuanyuan Chen · 1989 to 2026
$17.8M
Rise of lasR mutant Pseudomonas aeruginosa keratitisR01EY032517 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHANKS, ROBERT M · 2021 to 2024
$1.6M
Extensively drug resistant Pseudomonas aeruginosa keratitis outbreak strain:  virulence mechanisms and mitigationR01EY036686 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROBERT M SHANKS · 2024 to 2026
$1.4M
NEI NIH HHS P30 EY008098NEI NIH HHS P30 EY08098NEI NIH HHS R01EY032517NEI NIH HHS R01 EY036686NEI NIH HHS R01EY036686Research to Prevent Blindness N/AShionogi (United States) N/AThe Bruce and Barbara Wiegand Foundation N/AThe Charles and Estelle Campbell Foundation N/AThe Eye and Ear Foundation of Pittsburgh N/A
6 · The paper itself

Abstract

backgroundTo evaluate the potential of cefiderocol as a topical ophthalmic antibiotic by determining the susceptibility of keratitis isolates from an extensive panel of Gram-negative bacterial species to this siderophore-cephalosporin class antibiotic.

methodsMinimum Inhibitory Concentrations (MICs) of cefiderocol were determined by the broth dilution method using iron-depleted, cation-adjusted Mueller-Hinton broth. The following Gram-negative bacteria were included:

resultsMIC

conclusionsCefiderocol demonstrated in vitro activity against the tested panel of Gram-negative keratitis isolates. The results of this study suggest cefiderocol may be useful for the treatment of keratitis caused by numerous Gram-negative pathogens. Further development of cefiderocol for the topical treatment of Gram-negative keratitis is indicated.

Indexed as

antibioticcefiderocolGram-negative bacteriakeratitis

Identifiers

PMID42041311
PMCPMC13113829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.